LYEL:NASDAQ
Lyell Immunopharma Inc
၈.၁၂ US$
arrow_downward
-၀.၈၅%(-၀.၀၇၀) 1D
၈.၁၂ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: အောက် ၁၆, GMT-၄ ၁၆:၀၀:၀၁ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
၈.၂၄ US$
High
၈.၄၄ US$
Low
၇.၉၂ US$
Mkt. cap
၁၉.၉၀ ကုဋေ
Avg. vol.
၁.၅၈ သိန်း
Volume
၁.၉၅ သိန်း
52-wk high
၄၅.၀၀ US$
52-wk low
၇.၃၂ US$
EPS
-၁၂.၀၁ US$
Beta
-၀.၀၃
Shares outstanding
၂.၄၅ ကုဋေ
No. of employees
၁၆၁
Open
၈.၂၄ US$
High
၈.၄၄ US$
Low
၇.၉၂ US$
Mkt. cap
၁၉.၉၀ ကုဋေ
Avg. vol.
၁.၅၈ သိန်း
Volume
၁.၉၅ သိန်း
52-wk high
၄၅.၀၀ US$
52-wk low
၇.၃၂ US$
EPS
-၁၂.၀၁ US$
Beta
-၀.၀၃
Shares outstanding
၂.၄၅ ကုဋေ
No. of employees
၁၆၁
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၁ မိနစ်
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Simply Wall Street
·
ပြီးခဲ့သည့် ၁ နာရီ
Did Genetic Response Data Just Shift Madrigal Pharmaceuticals (MDGL) Investment Narrative?
MarketWatch
·
ပြီးခဲ့သည့် ၁ နာရီ
It was another great week for the average stock as market leadership shifts away from tech
CNN
·
ပြီးခဲ့သည့် ၁၇ နာရီ
Nasdaq sinks more than 2% as investors raise questions about AI debt
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees၁၆၁
Founded၂၀၁၈
HeadquartersSouth San Francisco, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitelyell.com